Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
CapsoVision Q4 2025 Earnings Call - Pivot to CapsoCam Colon Gen2 and AI as Small-Bowel Adoption Grows
CapsoVision closed 2025 with steady commercial traction in its CapsoCam Plus small-bowel capsule, modest top-line growth, and a clear shift of R&D resources toward a higher-spec CapsoCam Colon Gen 2 a...
- CapsoVision reported full-year revenue growth of approximately 15% year-over-year and a 21% increase in new account generation for 2025.
- Installed base exceeded 161,000 patients imaged with CapsoCam Plus as of December 31, 2025.
- Fourth quarter 2025 revenue was $3.9 million, up 13% versus Q4 2024; about 9,400 patients used CapsoCam Plus in Q4, a 12% year-over-year increase from ~8,374.
- +12 more takeaways
Rani Therapeutics Q4 2025 and Full Year 2025 Earnings Call - RT-114 Enters Phase I-B, first human PD test of RaniPill that could validate the platform
Rani closed 2025 with a string of strategic moves and a clear bet: prove the RaniPill works not just for pharmacokinetics, but for pharmacodynamics in humans. The company signed a collaboration with C...
- Rani signed a collaboration and license agreement with Chugai in October 2025, potential total value approximately $1.1 billion, including an option for Chugai to expand to up to five additional targets.
- Concurrent with the Chugai deal, Rani closed an oversubscribed $60.3 million private placement, including $6 million of debt conversion led by life science investors.
- Cash and marketable securities were $49.7 million as of December 31, 2025, up from $27.6 million at year-end 2024.
- +12 more takeaways
Wrap Technologies Q4 2025 Earnings Call - Pivot to integrated non-lethal response and 100% 2026 revenue growth target
Wrap says it is relaunching from a device vendor into a solutions company, bundling BolaWrap hardware with scaled digital training, policy support, evidence tools, and drone payloads. Management point...
- Company is repositioning from a device-only seller to an integrated non-lethal response system, combining BolaWrap hardware with WrapTactics training, Wrap Reality, WrapVision, policy support, and managed services.
- Management is targeting approximately 100% revenue growth in 2026, citing Q4 momentum and an unusually strong pipeline; that target excludes some larger federal opportunities they are pursuing.
- FY2025 gross revenue was $5.2 million, up 15% year over year; Q4 revenue was $1.4 million, up 62% year over year.
- +13 more takeaways
"INNOVATE Corp." Fourth Quarter 2025 Earnings Call - Infrastructure Surge from DBMG Lifts Revenue, But Margins and Leverage Signal Risk
INNOVATE closed Q4 2025 with a top-line beat driven almost entirely by its infrastructure arm, DBMG, which pushed consolidated revenue to $382.7 million and full-year revenue to $1.2 billion. DBMG’s b...
- Consolidated Q4 2025 revenue was $382.7 million, up 61.7% year over year, driven primarily by the infrastructure segment.
- Total adjusted EBITDA for Q4 2025 was $24.5 million, up from $15.0 million in the prior year quarter.
- Full year 2025 consolidated revenue reached $1.2 billion, with adjusted EBITDA of $67.2 million.
- +16 more takeaways
CV Sciences Q4 2025 Earnings Call - Margin Recovery and a Tight Path to Cash-Flow Break Even
CV Sciences reported a down year for top line, but a deliberate and measurable swing toward profitability. Revenue fell to $13.8 million in 2025 from $15.7 million in 2024, yet gross margins improved ...
- Full year 2025 revenue declined to $13.8 million from $15.7 million in 2024, reflecting continued category headwinds and lower unit sales.
- Gross margin expanded to 49% for 2025, up from 45.6% in 2024, driven by lower product and shipping costs and increased insourcing of manufacturing.
- Fourth quarter 2025 revenue was $3.3 million, down from $3.9 million in Q4 2024 and flat sequentially versus Q3 2025.
- +12 more takeaways
CMC Fiscal 2026 Q2 Earnings Call - Precast Acquisitions and TAG Drive Core EBITDA to $297.5M
CMC posted a blowout fiscal Q2 driven by operational fixes and two strategic precast acquisitions. Consolidated core EBITDA jumped 114% year over year to $297.5 million, helped by TAG productivity gai...
- Consolidated core EBITDA was $297.5 million in Q2, up 114% year over year, and core EBITDA margin rose to 14%, a 610 basis point improvement.
- Reported net earnings were $93 million, or $0.83 per diluted share; adjusted earnings were $130.1 million, or $1.16 per diluted share, after excluding certain acquisition and other items.
- CMC completed acquisitions of CP&P and Foley and entered the precast business, with precast contributing $33.6 million to Construction Solutions adjusted EBITDA in Q2.
- +17 more takeaways
REX American Resources Q4 & FY2025 Earnings Call - 45Z tax credit drives record EPS, One Earth expansion near completion
REX closed fiscal 2025 with record per-share earnings after recognizing roughly $28 million of 45Z tax credits and reporting all-time high annual ethanol volumes. The One Earth Energy expansion to 200...
- REX recognized approximately $28 million of 45Z tax credits in fiscal 2025 after regulations clarified, materially boosting Q4 and full-year results.
- Management states the realized 45Z benefit equates to roughly $0.10 per gallon on consolidated ethanol volumes for FY2025.
- One Earth Energy expansion is nearing completion, raising capacity to 200 million gallons per year, with testing and commissioning expected in fiscal 2026.
- +13 more takeaways
JBS 4Q 2025 Earnings Call - Record Revenue and Resilient Multi-Protein Platform Amid U.S. Cattle Tightness
JBS closed 2025 with record scale, reporting $23 billion in fourth quarter sales and $86 billion for the year, while management stressed that geographic and protein diversification insulated results f...
- Scale and record sales: Q4 revenue $23 billion, FY 2025 revenue $86 billion, the highest in company history.
- Mixed EBITDA metrics called out: CEO cited a Q4 EBITDA margin of 17.5%, while CFO reported adjusted EBITDA (IFRS) of $1.7 billion and a Q4 margin of 7.4% (U.S. GAAP adjusted EBITDA $1.5 billion, 6.5% margin).
- Profitability and earnings: Management reported net income around $450 million in Q4 and $2.0 billion for the year; CFO detailed Q4 net income $415 million (EPS $0.39) and adjusted FY net income of $2.2 billion (adjusted EPS $2.10).
- +12 more takeaways
H.B. Fuller Q1 2026 Earnings Call - Supply shock forces 10%+ global price hike, guidance raised as pricing offsets volume weakness
H.B. Fuller reported a defensible quarter, with adjusted EBITDA of $119 million, margins expanding as pricing, raw-material actions, and Project Quantum Leap restructuring more than offset a 6.6% orga...
- Organic revenue fell 6.6% year over year in Q1 2026, with pricing up 0.6% and volume down 7.2%.
- Adjusted EBITDA was $119 million, up 4% year over year, and adjusted EBITDA margin expanded 90 basis points to 15.4%.
- Management announced a minimum 10% global price increase, effective April 1, with higher adjustments for certain technologies and regions.
- +12 more takeaways
M-tron Industries Q4 FY2025 Earnings Call - 62% Backlog Surge, Rights Offering to Fund Defense-driven Expansion
M-tron closed FY2025 with a meaningful defense-led acceleration, a 62% jump in backlog to $76.4 million, and signs it is pivoting from organic growth to dealmaking. Q4 revenue was $14.2 million, up 11...
- Backlog jumped 62% year over year to $76.4 million at quarter end, driven primarily by defense programs and commercial avionics orders.
- Q4 revenue was $14.2 million, an 11.2% increase versus Q4 2024; full-year 2025 revenue was $54.4 million, also up 11.2% year over year.
- Q4 gross margin was 46.9% versus 47.2% a year earlier; full-year gross margin declined to 44.4% from 46.2% in 2024, with tariffs and an unfavorable new-product mix cited as the main drivers.
- +11 more takeaways